Quick answer
Extended answer
What are the most common research questions about Retatrutide?
Key facts
- Compound
- Retatrutide (LY3437943)
- Class
- Triple GLP-1 / GIP / GCG receptor agonist
- Status
- Investigational (phase 2 published)
- Use
- In-vitro reference standard
What is Retatrutide?
Retatrutide (developmental code LY3437943) is an investigational synthetic peptide characterised in the peer-reviewed literature as a single-molecule agonist of three related class B G-protein-coupled receptors: GLP-1R, GIPR and GCGR.
Which receptors does Retatrutide activate?
Retatrutide is reported as a balanced full agonist at the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR) and the glucagon receptor (GCGR).
How does Retatrutide differ from Semaglutide and Tirzepatide?
Semaglutide is a single agonist at GLP-1R. Tirzepatide is a dual agonist at GLP-1R and GIPR. Retatrutide adds a third receptor — GCGR — to the same molecule and is described as a triple agonist.
What is Retatrutide's molecular formula and weight?
The published molecular formula for Retatrutide is C226H344N50O68 with a reported molecular weight of approximately 4731 g/mol.
How should Retatrutide reference material be stored?
Lyophilised Retatrutide is stored at −20 °C, desiccated and protected from light. Reconstituted stocks are stored short-term at 2–8 °C and long-term as single-use aliquots at −20 °C, with freeze-thaw cycles minimised.
What diluent should be used to reconstitute Retatrutide?
Sterile or bacteriostatic water is the default diluent for the incretin-analogue peptide class. Always follow compound-specific documentation and the laboratory SOP.
What assays is Retatrutide commonly used in?
Common applications include cAMP functional assays at recombinant human GLP-1R, GIPR and GCGR; radioligand or fluorescent displacement binding at each receptor; and analytical HPLC and mass-spectrometry method development.
Is Retatrutide approved for clinical use?
As of the date of publication, Retatrutide is an investigational compound reported in phase 2 clinical trials in the peer-reviewed literature; it is not approved for therapeutic use in the United Kingdom.
Is Retatrutide supplied for human use?
No. Oxford Research Peptides supplies Retatrutide strictly as a reference standard for in-vitro laboratory research. Nothing in the product documentation constitutes medical advice or endorses any therapeutic use.
Where can I read the primary literature on Retatrutide?
Key primary sources include the Coskun et al. (2022) discovery pharmacology paper in Cell Metabolism, the Jastreboff et al. (2023) obesity trial in the New England Journal of Medicine and the Rosenstock et al. (2023) type 2 diabetes trial in the Lancet. Full citations are provided in the Retatrutide monograph reference list.
For deeper reading see the Retatrutide monograph, Mechanism of Action, Research Applications and the receptor guides for GLP-1R, GIPR and GCGR.
Evidence summary
- What is Retatrutide?
Introductory reference on Retatrutide (LY3437943) — a triple-agonist investigational peptide referenced in incretin pharmacology literature.
- Retatrutide Mechanism of Action
Receptor-level explanation of Retatrutide's activity at GLP-1R, GIPR and GCGR as reported in the published preclinical and clinical literature.
- GLP-1 Receptor Explained
Overview of the GLP-1 receptor: a Class B G-protein-coupled receptor central to incretin pharmacology and to a growing family of research peptides.
- GIP Receptor Explained
Overview of the GIP receptor: a class B G-protein-coupled receptor engaged by dual and triple incretin-agonist research peptides.
- Glucagon Receptor Explained
Overview of the glucagon receptor (GCGR): classification, hepatic signalling and its role as the third receptor in triple-agonist research peptides.
- Triple Agonists Explained
Educational overview of triple GLP-1 / GIP / glucagon receptor agonists — pharmacological rationale, structural strategy and comparison to single- and dual-agonist analogues.
Research use only
Publication information
- Published
- 2026-07-15
- Updated
- 2026-07-15
- Reviewed
- 2026-07-15
- Version
- 1.0
Revision history
- v1.02026-07-15· Editorial Team
Initial publication as part of the Retatrutide authority cluster (Release 4.0).
Editorial standards
Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.
Conflict of interest
Next scheduled review: 2028-01-15. Our research methodology describes how the review is conducted.